HSIC · 10-Q · 2026Q3 · Full report

Healthcare Regulation and Compliance

HENRY SCHEIN INC · 2026-11-03 · Importance 29 · Surprise 24

Henry Schein operates businesses involved in pharmaceuticals, medical devices, in vitro diagnostics, manufacturing, and direct-to-patient medical supplies, subjecting them to local, state, federal, and foreign requirements. The company reports increased government enforcement in health care, particularly concerning fraud and abuse, anti-bribery and anti-corruption, controlled-substance handling, medical-device regulation, and data privacy and security. Applicable rules also address hazardous substances and PFAS, chemical warnings, amalgam bans, pricing disclosures, human-trafficking and forced-labor transparency, workplace safety, and reimbursement rates; evolving implementation may affect operations and financial performance. Certain businesses must also meet complex coding, billing, and record-keeping requirements for federal, state, and commercial reimbursement programs, while government-contractor businesses face additional requirements.

Key facts

• Henry Schein’s businesses include distribution, manufacturing, importation, exportation, marketing, sale, and promotion of pharmaceuticals, medical devices, and in vitro diagnostics, subject to extensive local, state, federal, and foreign government laws and regulations. source
• Government enforcement in the health care sector has increased in areas including fraud and abuse, anti-bribery and anti-corruption, controlled-substance handling, medical-device regulation, and data privacy and security. source
• Certain Henry Schein businesses must comply with complex coding, billing, and record-keeping requirements to substantiate claims under federal, state, and commercial/private health care reimbursement programs. source